Stock 688177 BIO-THERA SOLUTIONS, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Bio-Thera Solutions, Ltd. Stock

Equities

688177

CNE100003R98

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
24.91 CNY +2.22% Intraday chart for Bio-Thera Solutions, Ltd. -10.14% -39.60%
Jun. 03 Bio-Thera Solutions Receives Positive CHMP Opinion for Avzivi (Bevacizumab), A Biosimilar Referencing Avastin CI
Jun. 02 Bio-Thera Solutions Presents Clinical Data for BAT8006 (Folate Receptor-Alpha-ADC) At the 2024 American Society of Clinical Oncology Annual Meeting CI

Financials

Sales 2024 * 1.35B 186M Sales 2025 * 2.13B 294M Capitalization 10.31B 1.42B
Net income 2024 * -145M -20.01M Net income 2025 * 215M 29.67M EV / Sales 2024 * 7.64 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 4.85 x
P/E ratio 2024 *
-72.2 x
P/E ratio 2025 *
47.9 x
Employees 1,167
Yield 2024 *
-
Yield 2025 *
-
Free-Float 20.8%
More Fundamentals * Assessed data

Chart Bio-Thera Solutions, Ltd.

Dynamic Chart

Latest news about Bio-Thera Solutions, Ltd.

Bio-Thera Solutions Receives Positive CHMP Opinion for Avzivi (Bevacizumab), A Biosimilar Referencing Avastin CI
Bio-Thera Solutions Presents Clinical Data for BAT8006 (Folate Receptor-Alpha-ADC) At the 2024 American Society of Clinical Oncology Annual Meeting CI
Bio-Thera Solutions Grants STADA European Commercialization Rights for BAT2506 Injection MT
Bio-Thera, Stada Enter Deal for Biosimilar Candidate to Johnson & Johnson's Simponi in EU, UK MT
Bio-Thera Solutions and STADA Arzneimittel AG Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK CI
China Gives Nod to Bio-Thera Solutions' Clinical Trials for Anti-Tumor Drug Combo MT
Bio-Thera Solutions Gets Nod to Trial Tumor Drug Combination MT
China Grants Clinical Trial Approval to Bio-Thera's Anti-Tumor Combination Therapy MT
Bio-Thera Solutions, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006 CI
Bio-Thera Solutions Grants Marketing Rights of Two Drugs to Latin American Company MT
Bio-Thera Solutions, Ltd. Partners with SteinCares to Market Two Biosimilars in LATAM CI
Bio-Thera Solutions, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Bio-Thera Solutions Announces Initiation of Phase IB / IIA Clinical Trial for BAT6026 CI
Bio-Thera Solutions Gets Regulatory Nod for Trial of Tumor Drug Combination Treatment MT
More news

Press releases Bio-Thera Solutions, Ltd.

Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK AQ
Bio-Thera Solutions Receives IND Clearance from US FDA to Initiate a Phase II Study for BAT8006, an Innovative Antibody Drug Conjugate Targeting Folate Receptor AQ
Recent Biosimilar Approvals AQ
Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litigation in the U.S AQ
Genentech Files BPCIA Complaint Against Biogen Regarding Tocilizumab AQ
More press releases

News in other languages on Bio-Thera Solutions, Ltd.

Sandoz pourra distribuer aux USA un biosimilaire chinois de l'Avastin de Roche
Sandoz-Partner erhält US-Zulassung für Biosimilar für Roche-Blockbuster
More news

Quotes and Performance

1 day+2.22%
1 week-10.14%
Current month-10.14%
1 month-28.17%
3 months-28.67%
6 months-43.92%
Current year-39.60%
More quotes

Highs and lows

1 week
24.20
Extreme 24.2
26.98
1 month
24.20
Extreme 24.2
32.90
Current year
24.03
Extreme 24.03
41.92
1 year
24.03
Extreme 24.03
47.46
3 years
17.09
Extreme 17.09
47.46
5 years
17.09
Extreme 17.09
78.00
10 years
17.09
Extreme 17.09
78.00
More quotes

Managers and Directors - Bio-Thera Solutions, Ltd.

Managers TitleAgeSince
Sheng Feng Li CEO
 Chief Executive Officer 65 03-07-27
Xian Hong Zhan DFI
 Director of Finance/CFO 46 19-04-18
Xiao Yun Wu CHM
 Chairman 43 10-12-31
Members of the board TitleAgeSince
De Han Huang BRD
 Director/Board Member 59 22-05-19
Sheng Feng Li CEO
 Chief Executive Officer 65 03-07-27
Jin Chen Yu BRD
 Director/Board Member 66 12-12-31
More insiders

Quotes

Date Price Change Volume
24-06-07 24.91 +2.22% 1,892,586
24-06-06 24.37 -6.09% 2,960,876
24-06-05 25.95 -2.63% 2,163,584
24-06-04 26.65 -0.52% 1,334,546
24-06-03 26.79 -3.35% 2,357,912

End-of-day quote Shanghai S.E., June 06, 2024

More quotes

Company Profile

Bio-Thera Solutions, Ltd. is a China-based company mainly engaged in the research and development of innovative drugs and biosimilars. The Company is committed to the development of a new generation of antibody drugs to treat cancer, autoimmune diseases, cardiovascular diseases and other major diseases that endanger human life and health. The Company's main products include adalimumab BAT1406, bevacizumab BAT1706, BAT8001, tocilizumab BAT1806, batifaban BAT2094, BAT8003 and so on.
Sector
Biotechnology & Medical Research
Calendar
2024-08-22 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
24.91 CNY
Average target price
42.1 CNY
Spread / Average Target
+69.01%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIO-THERA SOLUTIONS, LTD. Stock Bio-Thera Solutions, Ltd.
-39.60% 1.42B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.72% 125B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+14.19% 108B
BIONTECH SE Stock BioNTech SE
-4.93% 24.21B
ARGENX SE Stock argenx SE
+2.36% 22.78B
GENMAB A/S Stock Genmab A/S
-10.81% 17.96B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.74% 16.43B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.31% 16.37B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.44% 13.58B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.89% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 688177 Stock